WA-PATTERN-COMPUTER
21.6.2021 19:51:07 CEST | Business Wire | Press release
Pattern Computer,® Inc. (PCI) is excited to announce the discovery of new insights that can lead to significant reductions in the flights delays experienced across the United States.
According to the Federal Aviation Association (FAA)/Nextor, the estimated annual costs of delays, which includes direct costs to airlines and passengers, lost demand and indirect costs, in 2018 was $28 billion. Based on the Bureau of Transportation statistical data, 34% of all flights in 2018 experienced some type of departure delay and 18% of all flights experienced delays of 15 minutes or more, with an average delay of 66 minutes. The direct costs of those delays to airlines and passengers was $4.5 billion.
PCI’s team assembled a novel, integrated dataset which encompassed the FAA flight, aircraft and operational network data, and relevant US national weather data for the 7.2 million US commercial passenger flights in 2018.
Utilizing the Pattern Discovery Engine®, the PCI team was able to uncover a number of patterns underlying US commercial passenger flight delays. While many previous approaches focused on arrival delays, the PCI team chose to focus on flight departure delays as it more accurately reflects the operational efficiency of the individual airlines, as well as the airlines’ operational partnership with the FAA air traffic control facilities.
The most significant pattern, which was reflected as the top driver of delays in 11 of the 12 months, were flight departure delays due to weather factors along the route of travel, combined with the scheduled departure time (congestion). Together these two factors were the most consistent throughout the entirety of 2018. The flight leg for that day also played into this pattern in 10 of the 12 months as well – indicating that the cascading effect of flight delays continued to impact flights later in the day.
“When we used the Pattern Discovery Engine to understand the factors behind flight departure delays, we saw delays initiated by the FAA’s Traffic Management Initiatives due to en route weather as having created the most significant delays over the course of the year. The second most significant pattern was due to icing conditions at the departure airport, which also has cascading effects through the day for the impacted aircraft. A differentiating factor for Pattern Computer is that we do not see just one pattern; we see all the interrelated patterns in the dataset regarding a specific outcome in ranked order,” said Mark R. Anderson, CEO of Pattern Computer.
The newly discovered patterns indicate that most flight delays through the year were the results of significant weather events having regional limiting effects on the available flight routes. These large regional storms are typically predicted by the NOAA/FAA at least 48-72 hours in advance, airlines cancel flights ahead of the worst storms to avoid the high costs of long-delayed flights, including staffing costs, dissatisfied passengers, and crews cancelled due to duty-time expiration and required rest periods. While canceling flights is one option in reducing the costs of flight delays, the negative impact to customer satisfaction is high, and there is significant disruption to the airlines’ careful scheduling of crews, equipment and supporting staff. Too often the case is to carry on with the planned schedule and let the FAA determine how many planes are impacted as the weather event occurs. In many aspects, this is the same operating strategy as has been in effect for the past 4 decades.
“Due to the pandemic, the travel industry is facing a challenging period of uncertainty, but with that is the opportunity to improve operations, pricing, and offerings in a way that is future-ready. There is an opportunity to develop services tailored for the life styles, needs, and interests of business and leisure passengers alike. Post-pandemic, people are expecting a ‘new normal’ to emerge with many of the known patterns of life being different. Now is the time to introduce new capabilities, preparing for a post-pandemic swell in leisure travelers wishing to get out and travel,” said Bob Edwards, former CIO for United Airlines.
Without changes, the airlines will continue to bear substantial direct and indirect costs due to flight departure delays. But informed by these new Pattern discoveries, leading airlines could use technology, data and analytics combined with agility to create new solutions in the form of flexible scheduling, routing, pricing, and packaging to avoid these costs, which will only increase as the passenger loads begin to recover to their new normal, which may exceed the historical norms.
This work by Pattern Computer could allow informed, flexible scheduling. Dynamic load levels could be shifted and adjusted to the changing conditions, optimizing for costs, better utilizing available resources and resulting in more reliable schedules. Pattern is continually innovating and looking for ways to improve and optimize complex challenges in multiple industries, including the global airline industry, where new partnerships are now being sought.
The foregoing contains statements about the Pattern Computer’s future that are not statements of historical fact. These statements are “forward looking statements” for purposes of applicable securities laws, and are based on current information and/or management's good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.
About Pattern Computer
Pattern Computer, Inc., a Seattle-area startup, uses its proprietary Pattern Discovery Engine to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.
While the company is currently applying its computational platform to air traffic operations, it is also making pattern discoveries for partners in several other sectors, including drug discovery and biomedical research, materials science, aerospace manufacturing, veterinary medicine, and finance.
For more information on Pattern Computer Inc., visit: www.patterncomputer.com
For more information about Mark Anderson, visit: www.patterncomputer.com/founders/
Copyright © 2021 Pattern Computer, Inc. All Rights Reserved. Pattern Computer Inc., and PCI are trademarks of Pattern Computer, Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210621005713/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
